Amyloid Beta-directed Antibody class drugs

1 result
  • leqembi

    (lecanemab)
    Eisai Inc.
    LEQEMBI is indicated for treating Alzheimer’s disease in patients with mild cognitive impairment or mild dementia. Treatment should begin in this early stage, as demonstrated in clinical trials.